All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABY-035
Therapeutic Area: Immunology Product Name: ABY-035
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABY-035
Therapeutic Area: Dermatology Product Name: ABY-035
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include further indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABY-035
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Inmagene Biopharmaceuticals
Deal Size: $225.5 million Upfront Cash: $10.0 million
Deal Type: Partnership May 15, 2020
Details:
The parties will develop and commercialize ABY-035 for multiple auto-immune diseases. Inmagene will Commercialize ABY-035 in mainland China, Hong Kong, Taiwan, and Macau, and South Korea, and will run developmental activities in the Asia Pacific region.